iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer
January 10 2022 - 7:00AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of highly differentiated immuno-oncology
therapeutics for patients, today provided a clinical development
plan for its anti-TIGIT monoclonal antibody, EOS-448, and its A2A
receptor antagonist, inupadenant. iTeos also announced the
promotion of Yvonne McGrath, Ph.D., to chief scientific officer.
“We have generated significant momentum for both of our clinical
programs that have shown encouraging Phase 1 data: EOS-448, our
FcγR-engaging anti-TIGIT antibody and inupadenant, our potential
best-in-class A2A receptor antagonist. We are entering a period of
execution from a clinical development perspective, with 11 clinical
studies ongoing or expected to start, including three planned
registration-directed trials and novel immunotherapy combinations
in difficult-to-treat cancers,” said Michel Detheux, Ph.D.,
president and chief executive officer of iTeos. “I am also thrilled
to announce Dr. McGrath’s promotion to chief scientific officer.
Her leadership in our drug discovery and translational initiatives
and deep knowledge of tumor immunology, have resulted in iTeos
making tremendous progress in building a differentiated pipeline of
next generation immunotherapies and identifying opportunities for
new programs to take into the clinic. We look forward to continuing
this momentum and providing updates on our ongoing trials as they
progress, remaining focused on delivering potential therapies to
patients as safely and quickly as possible.”
Clinical Development Plans
EOS-448: IgG1 anti-TIGIT monoclonal antibody
designed to optimize its affinity, potency and activity, engage the
Fc gamma receptor (FcγR), and to enhance the anti-tumor response
through a multifaceted mechanism.
- iTeos plans to initiate various combinations of potential next
generation immuno-oncology agents:
- In partnership with GSK, the company is assessing the doublet
of GSK’s anti-PD-1 (dostarlimab) with EOS-448 in 1L PDL1high
non-small cell lung cancer, head and neck squamous cell carcinoma
and an additional indication in registration-directed trials. The
companies are also initiating trials with novel triplets, including
dostarlimab with EOS-448 and inupadenant as well as EOS-448 with
dostarlimab and GSK’s anti-CD96 antibody, GSK’608.
- iTeos is examining the doublet of pembrolizumab with EOS-448 in
patients with solid tumors in an ongoing Phase 1 trial and
inupadenant with EOS-448 in PD-1 resistant melanoma in an ongoing
Phase 2a trial.
- The company is advancing an ongoing open-label, multicenter,
dose-escalation/expansion Phase 1/2 trial evaluating the safety,
tolerability and preliminary activity of EOS-448, to the
combination phase with Bristol Myers Squibb’s immunomodulatory
imide drug (IMiD), iberdomide, with or without dexamethasone, in
adults with relapsed or refractory multiple myeloma, based on
strong preclinical data generated with Fred Hutchinson Cancer
Research Center.
Inupadenant (EOS-850): Designed as an
insurmountable and highly selective small molecule antagonist of
the adenosine A2A receptor, the only high-affinity adenosine
receptor expressed on different immune cells found in the tumor
micro-environment.
- iTeos plans to initiate a randomized Phase 2 trial in a solid
tumor indication to evaluate the combination of inupadenant with
chemotherapy compared to standard of care.
- The company is also evaluating inupadenant in combination with
pembrolizumab in PD-1 resistant melanoma in an ongoing Phase 2a
trial.
- iTeos is evaluating patient and indication selection biomarkers
in the ongoing Phase 1b/2a trial of inupadenant as a
monotherapy.
In the role of chief scientific officer, Dr. McGrath will be
responsible for the continued advancement of iTeos’s pipeline of
immunotherapy candidates in advanced cancers. She has served as
vice president of R&D since June 2020, bringing more than 20
years of experience in immuno-oncology, clinical development and
R&D. Prior to iTeos, Dr. McGrath served as the chief scientific
officer at Complix N.V. and as Head of Development at Immunocore.
She also held R&D management positions at Medigene and Biovex.
Dr. McGrath holds a Ph.D. from the University of Wales, College of
Medicine, UK.
“iTeos is deeply committed to making a difference for people
with cancer through the development of a growing pipeline of
candidates and original approaches, designed with the potential to
fully restore the immune response against cancer,” said Dr.
McGrath. “I am excited to continue to lead our team of R&D
scientists during this pivotal time for the company, applying our
deep knowledge of tumor immunology to design and develop
best-in-class therapeutics for patients.”
About iTeos Therapeutics, Inc.iTeos
Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of tumor
immunology and immunosuppressive pathways to design novel product
candidates with the potential to fully restore the immune response
against cancer. The Company’s innovative pipeline includes two
clinical-stage programs targeting novel, validated immuno-oncology
pathways designed with optimized pharmacologic properties for
improved clinical outcomes. The first antibody product candidate,
EOS-448, is a high affinity, potent, anti-TIGIT antibody with a
functional Fc domain, designed to enhance the anti-tumor response
through a multifaceted immune modulatory mechanism, currently
progressing in multiple indications in collaboration with GSK. The
Company is also advancing inupadenant, a next-generation adenosine
A2A receptor antagonist tailored to overcome cancer
immunosuppression into proof-of concept trials in several
indications following encouraging single-agent activity in Phase 1.
iTeos Therapeutics is headquartered in Cambridge, MA with a
research center in Gosselies, Belgium.
Internet Posting of InformationiTeos routinely
posts information that may be important to investors in the
‘Investors’ section of its website at www.iteostherapeutics.com.
The company encourages investors and potential investors to consult
our website regularly for important information about iTeos.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements that are not statements of
historical fact are forward-looking statements. Words such as
“believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,”
“prepare,” “look,” “potential,” “possible” and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements include statements relating to the
potential benefits of our product candidates, including their
potential to restore the immune response against cancer and the
potential of A2A to be best-in-class receptor antagonist; our
clinical trials plans; and the potential for certain studies to
support regulatory submissions.
These forward-looking statements involve risks and
uncertainties, many of which are beyond iTeos’ control. Actual
results could materially differ from those stated or implied by
these forward-looking statements as a result of such risks and
uncertainties. Known risk factors include the following: success in
preclinical testing and early clinical trials does not ensure that
later clinical trials will be successful, and early results from a
clinical trial do not necessarily predict final results; the data
for our product candidates may not be sufficient to support
regulatory approval; the expected benefits and opportunities
related to the agreement between iTeos and GSK may not be realized
or may take longer to realize than expected due to a variety of
reasons, including any inability of the parties to perform their
commitments and obligations under the agreement, challenges and
uncertainties inherent in product research and development and
manufacturing limitations; iTeos may not be able to execute on its
business plans, including meeting its expected or planned
regulatory milestones and timelines, research and clinical
development plans, and bringing its product candidates to market,
for various reasons, some of which may be outside of iTeos’
control, including possible limitations of company financial and
other resources, manufacturing limitations that may not be
anticipated or resolved for in a timely manner, regulatory, court
or agency decisions such as decisions by the United States Patent
and Trademark Office with respect to patents that cover our product
candidates and the impact of the COVID-19 pandemic; and those risks
identified under the heading “Risk Factors” in iTeos’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2021 filed
with the Securities and Exchange Commission (SEC) as well as other
SEC filings made by the Company which you are encouraged to
review.
Any of the foregoing risks could materially and adversely affect
iTeos’ business, results of operations and the trading price of
iTeos’ common stock. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release. iTeos does not undertake any obligation to publicly update
its forward-looking statements based on events or circumstances
after the date hereof.
For further information, please contact:
Investor Contacts:Ryan BakeriTeos Therapeutics,
Inc.Ryan.Baker@iteostherapeutics.com
Media Contacts:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Sep 2023 to Sep 2024